210 related articles for article (PubMed ID: 33037092)
1. Combination Strategies to Improve Targeted Radionuclide Therapy.
Chan TG; O'Neill E; Habjan C; Cornelissen B
J Nucl Med; 2020 Nov; 61(11):1544-1552. PubMed ID: 33037092
[TBL] [Abstract][Full Text] [Related]
2. Targeted radionuclide therapy in combined-modality regimens.
Gill MR; Falzone N; Du Y; Vallis KA
Lancet Oncol; 2017 Jul; 18(7):e414-e423. PubMed ID: 28677577
[TBL] [Abstract][Full Text] [Related]
3. Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment.
Kleinendorst SC; Oosterwijk E; Bussink J; Westdorp H; Konijnenberg MW; Heskamp S
Clin Cancer Res; 2022 Sep; 28(17):3652-3657. PubMed ID: 35471557
[TBL] [Abstract][Full Text] [Related]
4. The HSP90 inhibitor onalespib potentiates 177Lu‑DOTATATE therapy in neuroendocrine tumor cells.
Lundsten S; Spiegelberg D; Stenerlöw B; Nestor M
Int J Oncol; 2019 Dec; 55(6):1287-1295. PubMed ID: 31638190
[TBL] [Abstract][Full Text] [Related]
5. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
6. High-Specific-Activity-
Jha A; Taïeb D; Carrasquillo JA; Pryma DA; Patel M; Millo C; de Herder WW; Del Rivero J; Crona J; Shulkin BL; Virgolini I; Chen AP; Mittal BR; Basu S; Dillon JS; Hope TA; Mari Aparici C; Iagaru AH; Hicks RJ; Avram AM; Strosberg JR; Civelek AC; Lin FI; Pandit-Taskar N; Pacak K
Clin Cancer Res; 2021 Jun; 27(11):2989-2995. PubMed ID: 33685867
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment.
Ruigrok EAM; Verkaik NS; de Blois E; de Ridder C; Stuurman D; Roobol SJ; Van Gent DC; de Jong M; Van Weerden WM; Nonnekens J
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887398
[TBL] [Abstract][Full Text] [Related]
9. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase I-targeting drugs as radiation sensitizers.
Chen AY; Choy H; Rothenberg ML
Oncology (Williston Park); 1999 Oct; 13(10 Suppl 5):39-46. PubMed ID: 10550825
[TBL] [Abstract][Full Text] [Related]
11. [Targeted therapies and radiation therapy in non-small cell lung cancer].
Rivera S; Quéro L; Wong Hee Kam S; Maylin C; Deutsch E; Hennequin C
Cancer Radiother; 2011 Oct; 15(6-7):527-35. PubMed ID: 21885318
[TBL] [Abstract][Full Text] [Related]
12. Combined Targeted Radiopharmaceutical Therapy and Immune Checkpoint Blockade: From Preclinical Advances to the Clinic.
Bellavia MC; Patel RB; Anderson CJ
J Nucl Med; 2022 Nov; 63(11):1636-1641. PubMed ID: 36215570
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer.
Damiana TST; Dalm SU
Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34067215
[TBL] [Abstract][Full Text] [Related]
14. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
[TBL] [Abstract][Full Text] [Related]
15. Imaging DNA Damage Repair In Vivo After
O'Neill E; Kersemans V; Allen PD; Terry SYA; Torres JB; Mosley M; Smart S; Lee BQ; Falzone N; Vallis KA; Konijnenberg MW; de Jong M; Nonnekens J; Cornelissen B
J Nucl Med; 2020 May; 61(5):743-750. PubMed ID: 31757844
[TBL] [Abstract][Full Text] [Related]
16. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.
Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT
Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.
De Jong M; Valkema R; Jamar F; Kvols LK; Kwekkeboom DJ; Breeman WA; Bakker WH; Smith C; Pauwels S; Krenning EP
Semin Nucl Med; 2002 Apr; 32(2):133-40. PubMed ID: 11965608
[TBL] [Abstract][Full Text] [Related]
18. [Inhibitors of the heat shock protein 90 activity: a novel class of tumor radiosensitizers].
Kabakov AE; Kudriavtsev VA; Makarova IuM
Radiats Biol Radioecol; 2010; 50(5):528-35. PubMed ID: 21261003
[TBL] [Abstract][Full Text] [Related]
19. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
20. Strategizing the clone wars: pharmacological control of cellular sensitivity to radiation.
Kimple RJ
Mol Interv; 2010 Dec; 10(6):341-53. PubMed ID: 21263160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
